The Tough Tech problem we are solving
Current treatments for gut diseases like peptic ulcers, IBD, and bacterial overgrowth rely on broad-spectrum antibiotics and drugs that disrupt the microbiome, leading to recurrence and resistance without addressing root causes. Developing targeted microbiome therapies is challenging due to the complexity of engineering stable, effective probiotics that survive the gut environment and deliver precise therapeutic effects.
About our solution
Concordance Therapeutics engineers probiotics as precision therapeutics using synthetic biology to target gut diseases, improving outcomes for conditions like IBD and ulcers. These orally delivered "food medicines" restore microbiome balance with engineered microbes designed for safety, efficacy, and scalability across clinical applications.